The role of the low-density lipoprotein receptor-related protein (LRP) in the plasma clearance and liver uptake of recombinant single-chain urokinase-type plasminogen activator in rats

Thrombosis and Haemostasis

Volumn 77, Issue 4, 1997, Pages 710-717

  Van Der Kaaden, Marieke E ^a,c   Rijken, Dingeman C ^b   Kruijt, J Kar ^a   Van Berkel, Theo J C ^a   Kuiper, Johan ^a  

^a LEIDEN UNIVERSITY   (Netherlands)

^b TNO   (Netherlands)

^c LEIDEN UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

LOW DENSITY LIPOPROTEIN RECEPTOR; RECEPTOR PROTEIN; RECOMBINANT PLASMINOGEN ACTIVATOR; UROKINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DELETION MUTANT; DRUG CLEARANCE; DRUG UPTAKE; ENDOTHELIUM CELL; INTRAVENOUS DRUG ADMINISTRATION; ISOTOPE LABELING; KUPFFER CELL; LIVER CELL; LIVER PARENCHYMA; MALE; NONHUMAN; PLASMA CLEARANCE; PRIORITY JOURNAL; RAT; RECEPTOR BINDING;

EID: 0030974573     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1656039     Document Type: Article

References (59)

1. Kasai S, Arimura H, Nishida M, Suyama T. Proteolytic cleavage of single-chain pro-urokinase induces a conformational change which follows activation of the zymogen and reduction of its high affinity for fibrin. J Biol Chem 1985; 260: 12377-81.
2. Wijngaards G, Rijken DC, van Wezel AL, Groeneveld E, van der Velden CAM. Characterization and fibrin-binding properties of different molecular forms of pro-urokinase from a monkey kidney cell culture. Thromb Res 1986; 42: 749-60.
3. Danø K, Andreasen PA, Grondahl-Hansen J, Kristensen P, Nielsen LS, Skriver L. Plasminogen activators, tissue degradation and cancer. Adv Cancer Res 1985; 44: 139-4.
4. Eaton DL, Scott RW, Baker JB. 1984. Purification of human fibroblast urokinase proenzyme and analysis of its regulation by proteases and protease nexin. J Biol Chem 1984; 259: 6241-7.
5. Gurewich V, Pannel R, Louie S, Kelley P, Suddith RL, Greenlee R. Effective and fibrin-specific clot lysis by a zymogen precursor form of urokinase (pro-urokinase): a study in vitro and in two animal species. J Clin Invest 1984; 73: 1731-9.
6. Rijken DC, Binnema DJ, Los P. Specific fibrinolytic properties of different molecular forms of pro-urokinase from a monkey kidney cell culture. Thromb Res 1986; 42: 761-8.
7. Collen D, Zamarron DC, Lijnen HR, Hoylaerts M. Activation of plasminogen by pro-urokinase. J Biol Chem 1986; 261: 1259-66.
8. Lijnen HR, van Hoef B, Collen D. Comparative kinetic analysis of the activation of human plasminogen by natural and recombinant single-chain urokinase-type plasminogen activator. Biochim Biophys Acta 1986; 884:402-8.
9. Liu J, Pannell R, Gurewich V. A transitional state of pro-urokinase that has a higher catalytic efficiency against glu-plasminogen than urokinase. J Biol Chem 1992; 267: 15289-92.
10. Pannell R, Gurewich V. Pro-urokinase: a study of its stability in plasma and of a mechanism for its selective fibrinolytic effect. Blood 1986; 67: 1215-23.
11. Loscalzo J, Wharton TP, Kirschenbaum JM, Levine HJ, Flaherty JT, Topol EJ, Ramaswamy K, Kosowsky BD, Salem DN, Ganz P, Brinker JA, Gurewich V, Muller JE, and the Pro-urokinase for Mycardial infarction study group. Clot-selective coronary thrombolysis with pro-urokinase. Circulation 1989; 79: 776-82.
12. PRIMI trial study group. A randomised double blind trial of recombinant prourokinase against streptokinase in acute myocardial infarction. Lancet 1989; i: 863-8.
13. Collen D, de Cock F. Lijnen HR. Biological and thrombolytic properties of proenzyme and active forms of human urokinase. Turnover of natural and recombinant urokinase in rabbits and squirrel monkeys. Thromb Haemost 1984; 52: 24-6.
14. Spriggs DJ, Stassen JM, Hashimoto Y, Collen D. Thrombolytic properties of human tissue-type plasminogen activator, single-chain urokinase-type plasminogen activator, and synergistic combinations in venous thrombosis models in dogs and rabbits. Blood 1989; 73: 1207-12.
15. Stump DC, Lijnen HR, Collen D. Purification and characterization of a novel low molecular weight form of single-chain urokinase-type plasminogen activator. J Biol Chem 1986; 261: 17120-6.
16. Ueno T, Kobayashi N, Maekawa T. Studies on metabolism of urokinase and mechanism of thrombolysis by urokinase. Thromb Haemost 1979; 42: 885-94.
17. Kuiper J, Rijken DC. de Munk GAW, van Berkel ThJC. In vivo and in vitro interaction of high and low molecular weight single-chain urokinase-type plasminogen activator with rat liver cells. J Biol Chem 1992; 267: 1589-95.
18. Van der Kaaden ME, Kuiper J, Groeneveld E, van Berkel ThJC, Rijken DC. Clearance of urinary urokinase-type plasminogen activator by the asialoglycoprotein receptor and proteoglycans on rat parenchymal liver cells (Submitted).
19. Van der Kaaden ME, Rijken DC, Groeneveld E, van Berkel ThJC, Kuiper J. Native and non-glycosylated recombinant single-chain urokinase-type plasminogen activator are recognized by different receptor systems on rat parenchymal liver cells. Thromb Haemost 1995; 74: 722-9.
20. 2-macroglubulin receptor mediated cellular degradation of urokinase receptor bound complexes. J Biol Chem 1992; 267: 14543-6.
21. Herz J, Kowal RC, Goldstein JL, Brown MS. Proteolytic processing of the 600 kd low density lipoprotein receptor-related protein (LRP) occurs in a trans-Golgi compartment. EMBO J 1990; 9: 1769-76.
22. 2-macroglobulin. J Cell Biol 1990; 110: 1041-8.
23. 2-macroglobulin receptor as an approximately 440-kDa single chain protein. J Biol Chem 1989; 264: 15574-7.
24. Herz J, Hamann U, Rogne SM, Myklebost O, Gausepohl H, Stanley KK. Surface location and high affinity for calcium of a 500 kD liver membrane protein closely related to the LDL-receptor suggest a physiological role as lipoprotein receptor. EMBO J 1988; 7: 4119-27.
25. 2-macroglobulin receptor and low density lipoprotein receptor-related protein suggests that this molecule is a multifunctional receptor. J Biol Chem 1990; 265: 17401-4.
26. Bu G, Geuze HJ, Strous GJ, Schwartz AL. 39 kDa receptor-associated protein and molecular chaperone for LDL receptor-related protein. EMBO J 1995; 14: 2269-80.
27. Kowal RC, Herz J, Weisgraber KH, Mahley RW, Brown MS, Goldstein JL. Opposing effects of apolipoproteins E and C on lipoprotein binding of low density lipoprotein receptor-related protein. J Biol Chem 1990; 265: 10771-9.
28. Beisiegel U, Weber W, Bengtsson-Olivecrona G. Lipoprotein lipase enhances the binding of chylomicron remnants to low density lipoprotein receptor-related protein. Proc Natl Acad Sci USA 1991; 88: 8342-6.
29. 2-macroglobulin receptor/low density lipoprotein receptor-related protein binds and internalizes Pseudomonas exotoxin A. J Biol Chem 1992; 267: 12420-3.
30. 2MR is a hepatic receptor for tissue-type plasminogen activator. Proc Natl Acad Sci USA 1992; 89: 7427-31.
31. 2-macroglobulin receptor mediates cellular uptake of pro-urokinase. J Biol Chem 1993; 268: 21862-7.
32. Herz J, Clouthier DE, Hammer RE. LDL receptor-related protein internalizes and degrades uPA-PAI-1 complexes and is essential for embryo implantation. Cell 1992; 71: 411-21.
33. 2-macroglobulin receptor. Proc Natl Acad Sci USA 1992; 89: 7422-6.
34. Willnow TE, Armstrong SA, Hammer RE, Herz J. Functional expression of low density lipoprotein receptor-related protein is controlled by receptor associated protein in vivo. Proc Natl Acad Sci USA 1995; 92: 4537-41.
35. Orsini G, Brandazza A, Sarmientos P, Molinari A, Lansen J, Cauet G. Efficient renaturation and fibrinolytic properties of pro-urokinase and a deletion mutant expressed in Escherichia coli as inclusion bodies. Eur J Biochem 1991; 195: 691-7.
36. 2-macroglobulin-receptor site. Biochem J 1991; 279: 863-70.
37. 2-macroglobulin-trypsin complex in the rat is mainly accounted for by uptake into hepatocytes. Biochim Biophys Acta 1985; 846: 85-92.
38. 2-macroglobulin receptor. J Biol Chem 1991; 266: 21232-8.
39. Bijsterbosch MK, Ziere GJ, van Berkel ThJC. Lactosylated low density lipoprotein: a potential carrier for the site-specific delivery of drugs to Kupffer cells. Mol Pharmacol 1989; 36: 484-9.
40. Caster WO, Simon AB, Armstrong WD. Evans blue space in tissues of the rat. Am J Physiol 1955; 183: 317-21.
41. Kuiper J, Otter M, Rijken DC, van Berkel ThJC. Characterization of the interaction in vivo of tissue-type plasminogen activator with liver cells. J Biol Chem 1988; 263: 18220-4.
42. Van Berkel ThJC, de Rijke YB, Kruyt JK. Differential fate in vivo of oxidatively modified LDL and acetylated LDL in rats. Recognition by various scavenger receptors on Kupffer and endothelial cells. J Biol Chem 1991; 266: 2282-9.
43. Nagelkerke JF, Barto KP, van Berkel ThJC. In vivo and in vitro uptake and degradation of acetylated low density lipoprotein by rat liver endothelial, Kupffer and parenchymal cells. J Biol Chem 1983; 258: 12221-7.
44. Van Berkel ThJC, Dekker CJ, Kruyt JK, van Eijk HG. The interaction of transferrin and asialotransferrin with liver cells. Biochem J 1987; 243: 715-22.
45. Seglen PO. Isolation of liver cells. Meth Cell Biol 1976; 13: 29-83.
46. r activator. FEBS Lett 1986; 201: 193-7.
47. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the folin phenol reagent. J Biol Chem 1951; 255: 6111-20.
48. Van Berkel ThJC, Kruijt JK, Spanjer HH, Nagelkerke JF, Harkes L, Kempen HJM. The efficacy of a water-soluble tris-galactoside-terminated cholesterol derivative on the fate of low density lipoproteins and liposomes. J Biol Chem 1983; 260: 2694-9.
49. Van Berkel ThJC, Kruijt JK, Kempen HJM. Specific targeting of high density lipoprotein to liver hepatocytes by incorporation of tris-galactoside-terminated cholesterol derivative. J Biol Chem 1985; 260: 12203-7.
50. 2-macroglobulim by rat liver. Biochem J 1992; 287: 447-55.
51. 2MR, and the receptor associated protein (RAP). J of Histochem and Cytochem 1994; 42: 531-42.
52. 2-macroglobulin receptor/low density lipoprotein receptor-related protein. J Biol Chem 1994; 269: 25668-76.
53. Breton J, Pezzi N, Molinari A, Bonomini L, Lansen J, Gonzalez de Buitargo G, Prieto I. Prolonged half-life in the circulation of a chemical conjugate between a pro-urokinase derivative and human serum albumin. Eur J Biochem 1995; 231: 563-9.
54. Appella E, Robinson EA, Ullrich SJ, Stoppelli MP, Corti A, Cassani G, Blasi F. The receptor-binding sequence of urokinase. A biological function for the growth factor module of proteases. J Biol Chem 1987; 262:4437-40.
55. Estreicher A, Wohlwend A, Belin D, Schleuning WD, Vassalli JD. Characterization of the cellular binding site for the urokinase-type plasminogen activator. J Biol Chem 1989; 264: 1180-9.
56. Rabbani SA, Rajwans N, Achbarou A, Murthy KK, Goltzman D. Isolation and characterization of multiple isoforms of the rat urokinase receptor in osteoblasts. FEBS Lett 1994; 338: 69-74.
57. Pannell R, Gurewich V. Pro-urokinase: a study of its stability in plasma and of a mechanism for its selective fibrinolytic effect. Blood 1986; 5: 1215-1223.
58. Kuiper J, Kamps JAAM, van Berkel ThJC. Identification of the inhibitor of the plasminogen activator as the major secreted protein by endothelial rat liver cells. FEBS Lett 1989; 245: 229-34.
59. Quax PHA, van den Hoogen CM, Verheijen JH, Padro T, Zeheb R, Gelehrter TD, van Berkel ThJC, Kuiper J, Emeis JJ. Endotoxin induction of plasminogen activator and plasminogen activator inhibitor type-1 mRNA in rat tissues in vivo. J Biol Chem 1990; 265: 15560-3.